Cellular therapies have been the latest hype in the treatment of blood cancers. In 2017, two CAR T-cell therapies were approved by the Food and Drug Administration (FDA) for the treatment of acute lymphoblastic leukemia (ALL) and advanced lymphomas. John Gribben, MD, DSc, FRCPath, FMed Sci from the Barts Cancer Institute, London, UK discusses some of the advances in this field presented at the European Bone Marrow Transplant 2018 Annual meeting, held in Lisbon Portugal.